We've put some small files called cookies on your device to make our site work.
We'd also like to use analytics cookies. These send anonymous information about how our site is used to a service called Google Analytics & Hotjar Analytics. We use this information to improve our site.
Let us know if this is OK. We'll use a cookie to save your choice. You can read more about our cookies before you choose.
Authored by Dr Karthik Ramasamy, Oxford University Hospitals NHS Trust, Associate Professor of Haematology & Consultant Haematologist - Dr Jenny Bird, Bristol Haematology and Oncology Centre, Consultant Haematologist - Professor Mark Drayson, University Hospital Birmingham & Heartlands Hospital, Emeritus Professor of Clinical Immunodiagnostics and Honorary Consultant Immunologist - Lisa Ferguson, Oxford University Hospitals NHS Foundation Trust, Myeloma Advanced Nurse Practitioner - Dr Simon Stern, Epsom & St Helier University Hospitals NHS Trust, Consultant Haematologist - Myeloma UK
Authored by Prof. Ashutosh Wechalekar, University College London and the Royal Free London NHS Foundation Trust, UK, Professor of Medicine and Haematology - Dr Christopher Parrish, Leeds Teaching Hospitals NHS Trust, UK, Consultant Haematologist - Prof. Efstathios Kastritis, National and Kapodistrian University of Athens, School of Medicine, Greece, Professor of Clinical Therapeutics/Medical Oncology - Dr Jennifer Pinney, University Hospitals Birmingham NHS Foundation Trust, UK, Consultant Nephrologist - Dr Carol Whelan, Royal Free London NHS Foundation Trust, UK, Consultant Cardiologist - Prof. Giovanni Palladini, Amyloidosis Research and Treatment Center, University Hospital San Matteo, Pavia, Italy, Acting Director of the Amyloidosis Research and Treatment Center - Prof. Guy Pratt, University Hospitals Birmingham, UK, Consultant Haematologist - Myeloma UK